# A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive

Source: https://onco.cc/trials/nct05879822/  
OnCo record `nct05879822` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of INCB099280 in advanced solid tumours, run by Incyte Corporation, active and no longer recruiting.

## Summary

A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive is a phase 2 interventional study registered as NCT05879822 by Incyte Corporation, with 73 participants enrolled, started 2023-10-30 and due to reach its primary completion in 2026-09-30. Interventions recorded: INCB099280.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05879822
- Phase: 2
- Setting: A Phase 2 Study Evaluating INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive
- Sponsor: Incyte Corporation
- Enrolled: 73

## Sources

- ClinicalTrials.gov NCT05879822: https://clinicaltrials.gov/study/NCT05879822

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Incyte](https://onco.cc/companies/incyte/)

---
JSON: https://onco.cc/api/v1/entities/nct05879822.json